Paltusotine (CRN00808) is an orally active, nonpeptide selective somatostatin type 2 (SST2) receptor agonist, has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.
[1] Luo R, et al. Journal of the Endocrine Society, Volume 5, Issue Supplement_1, April-May 2021, Page A524.
















